1. Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors. Issue 12 (8th October 2019) Authors: Imai, Hisao; Kaira, Kyoichi; Mori, Keita; Kotake, Mie; Mitani, Masumi; Kawashima, Naoko; Hisada, Takeshi; Minato, Koichi Journal: Thoracic cancer Issue: Volume 10:Issue 12(2019) Page Start: 2200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗